Order Article Reprints

Agiannitopoulos K, Potska K, Katseli A, Ntogka C, Tsaousis GN, Pepe G, Bouzarelou D, Tsoulos N, Papathanasiou A, Ziogas D, et al. Only 32.3% of Breast Cancer Families with Pathogenic Variants in Cancer Genes Utilized Cascade Genetic Testing. Cancers. 2023; 15(21):5218. https://doi.org/10.3390/cancers15215218

Agiannitopoulos, Konstantinos, Kevisa Potska, Anastasia Katseli, Christina Ntogka, Georgios N. Tsaousis, Georgia Pepe, Dimitra Bouzarelou, Nikolaos Tsoulos, Athanasios Papathanasiou, Dimitrios Ziogas, and et al. 2023. "Only 32.3% of Breast Cancer Families with Pathogenic Variants in Cancer Genes Utilized Cascade Genetic Testing" Cancers 15, no. 21: 5218. https://doi.org/10.3390/cancers15215218

Agiannitopoulos, K., Potska, K., Katseli, A., Ntogka, C., Tsaousis, G. N., Pepe, G., Bouzarelou, D., Tsoulos, N., Papathanasiou, A., Ziogas, D., Venizelos, V., Markopoulos, C., Iosifidou, R., Karageorgopoulou, S., Giassas, S., Natsiopoulos, I., Papazisis, K., Vasilaki-Antonatou, M., Psyrri, A., ... Nasioulas, G. (2023). Only 32.3% of Breast Cancer Families with Pathogenic Variants in Cancer Genes Utilized Cascade Genetic Testing. Cancers, 15(21), 5218. https://doi.org/10.3390/cancers15215218